Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

References

• Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–e447. doi:10.1016/S2352-3018(18)30132-2
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860. doi:10.1056/nejm199803263381301
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–384. doi:10.1016/s0140-6736(05)67022-5
   PubMed Web of Science ®Google Scholar
• Farnham PG, Gopalappa C, Sansom SL, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–189. doi:10.1097/QAI.0b013e3182973966
   PubMed Web of Science ®Google Scholar
• Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open. 2020;3(6):e207954. doi:10.1001/jamanetworkopen.2020.7954
   PubMed Web of Science ®Google Scholar
• Losina E, Hyle EP, Borre ED, et al. Projecting 10-year, 20-year, and lifetime risks of cardiovascular disease in persons living with human immunodeficiency virus in the United States. Clin Infect Dis. 2017;65(8):1266–1271. doi:10.1093/cid/cix547
   PubMed Web of Science ®Google Scholar
• Siddiqi KA, Ostermann J, Zhang J, Khan MM, Olatosi B. Ageing with HIV in the United States: changing trends in inpatient hospital stays and comorbidities, 2003-2015. HIV Med. 2023;24(1):93–103. doi:10.1111/hiv.13325
   PubMed Web of Science ®Google Scholar
• Koethe JR, Jenkins CA, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32(1):50–58. doi:10.1089/aid.2015.0147
   PubMed Web of Science ®Google Scholar
• McComsey GA, Emond B, Shah A, et al. Association between weight gain and the incidence of cardiometabolic conditions among people living with HIV-1 at high risk of weight gain initiated on antiretroviral therapy. Infect Dis Ther. 2022;11(5):1883–1899. doi:10.1007/s40121-022-00673-1
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed October 5, 2022.
   Google Scholar
• Hester EK, Greenlee S, Durham SH. Weight changes with integrase strand transfer inhibitor therapy in the management of HIV infection: a systematic review. Ann Pharmacother. 2022;10600280211073321. doi:10.1177/10600280211073321
   Web of Science ®Google Scholar
• Chow W, Donga P, Côté-Sergent A, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr Med Res Opin. 2020;36(8):1313–1323. doi:10.1080/03007995.2020.1775074
   PubMed Web of Science ®Google Scholar
• Emond B, Rossi C, Cote-Sergent A, et al. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Curr Med Res Opin. 2022;38(2):287–298. doi:10.1080/03007995.2021.2007006
   PubMed Web of Science ®Google Scholar
• Bourgi K, Ofner S, Musick B, et al. Weight gain among treatment-naive persons with HIV receiving dolutegravir in Kenya. J Acquir Immune Defic Syndr. 2022;91(5):490–496. doi:10.1097/QAI.0000000000003087
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274. doi:10.1093/cid/ciz407
   PubMed Web of Science ®Google Scholar
• Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484. doi:10.1002/jia2.25484
   PubMed Web of Science ®Google Scholar
• Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P. Real-world analysis of weight gain and body mass index increase among patients with HIV-1 using antiretroviral regimen containing tenofovir alafenamide, tenofovir disoproxil fumarate, or neither in the United States. J Health Econ Outcomes Res. 2022;9(1):39–49. doi:10.36469/jheor.2022.31825
   PubMedGoogle Scholar
• Gomez M, Seybold U, Roider J, Harter G, Bogner JR. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German University Hospital in 2015-2017. Infection. 2019;47(1):95–102. doi:10.1007/s15010-018-1227-0
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389. doi:10.1093/cid/ciz999
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Sassa KN, O’Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019;6(10):ofz414. doi:10.1093/ofid/ofz414
   PubMed Web of Science ®Google Scholar
• Taramasso L, Berruti M, Briano F, Di Biagio A. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS. 2020;34(6):877–881. doi:10.1097/QAD.0000000000002496
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. doi:10.1056/NEJMoa1902824
   PubMed Web of Science ®Google Scholar
• Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–1859. doi:10.1093/cid/civ192
   PubMed Web of Science ®Google Scholar
• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne). 2018;9:705. doi:10.3389/fendo.2018.00705
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Defining Adult Overweight & Obesity. Available from: https://www.cdc.gov/obesity/basics/adult-defining.html. Accessed February 27, 2023.
   Google Scholar
• Achhra AC, Sabin C, Ryom L, et al. Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals: d: a: d cohort analysis. J Acquir Immune Defic Syndr. 2018;78(5):579–588. doi:10.1097/QAI.0000000000001722
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–1234.
   Web of Science ®Google Scholar
• Chen YW, Anderson D, Pericone CD, Donga P. Real-world assessment of weight change in African American females and Hispanics with HIV-1 after initiating integrase strand-transfer inhibitors or protease inhibitors. J Health Econ Outcomes Res. 2022;9(1):1–10. doi:10.36469/001c.30184
   PubMedGoogle Scholar
• Chen YW, Hardy H, Pericone CD, Chow W. Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors. J Health Econ Outcomes Res. 2020;7(2):102–110. doi:10.36469/jheor.2020.13457
   PubMedGoogle Scholar
• Kline MDA, Daniels C, Xu X, et al. Antiretroviral therapy anchor-based trends in body mass index following treatment initiation among military personnel with HIV. Mil Med. 2021;186(3–4):279–285. doi:10.1093/milmed/usaa416
   PubMed Web of Science ®Google Scholar
• Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase strand transfer inhibitor use in women. Clin Infect Dis. 2020;71(3):593–600. doi:10.1093/cid/ciz853
   PubMed Web of Science ®Google Scholar
• Grabar S, Potard V, Piroth L, et al. Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort. J Antimicrob Chemother. 1093;1:67.
   PubMedGoogle Scholar
• Kanters S, Renaud F, Rangaraj A, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. EClinicalMedicine. 2022;48:101412. doi:10.1016/j.eclinm.2022.101412
   PubMedGoogle Scholar
• Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–268. doi:10.1111/hiv.12294
   PubMed Web of Science ®Google Scholar
• Bannister WP, Mast TC, de Wit S, et al. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens. AIDS. 2022;36(15):2107–2119. doi:10.1097/QAD.0000000000003332
   PubMed Web of Science ®Google Scholar
• McCann K, Shah S, Hindley L, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021;35(10):1657–1665. doi:10.1097/qad.0000000000002930
   PubMed Web of Science ®Google Scholar
• Petoumenos K, Kuwanda L, Ryom L, et al. Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: results From the D:A:D Study. J Acquir Immune Defic Syndr. 2021;86(5):579–586. doi:10.1097/qai.0000000000002603
   PubMed Web of Science ®Google Scholar